SCHEMBL17508372

SCHEMBL17508372

Clc1cc(-c2cccc(-c3ccccc3)c2)c2ccccc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
KDM4E B2RXH2 3/20 0.42
ACACA Q13085 2/20 0.42
EGFR P00533 1/20 0.42
LTB4R Q15722 1/20 0.41
HTT P42858 3/20 0.41
USP2 O75604 1/20 0.41
MAPT P10636 1/20 0.40
NR1I3 Q14994 1/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
LMNA P02545 2/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
ACHE P22303 1/20 0.39
BMPR1B O00238 1/20 0.38
BMPR1A P36894 1/20 0.38
ACVR1B P36896 1/20 0.38
ACVRL1 P37023 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17508350 0.89 ACACA (0.51) MAOAMAOBKDM4EACACAEGFR
SCHEMBL4083079 0.89 ACACA (0.50) MAOAMAOBKDM4EACACAEGFR
SCHEMBL29352882 0.89 ACACA (0.50) MAOAMAOBKDM4EACACAEGFR
SCHEMBL18503975 0.82 ACACA (0.56) KDM4EACACAEGFRMAPTLMNA
SCHEMBL10631071 0.82 ABCG2 (0.48) KDM4EHTTESR1LMNAABCG2
SCHEMBL17508354 0.81 GSTP1 (0.46) MAOAMAOBKDM4EACACAHTT
SCHEMBL10629041 0.81 LTB4R (0.50) MAOAMAOBKDM4EACACALTB4R
SCHEMBL18504006 0.81 ACACA (0.55) KDM4EACACAEGFRMAPTLMNA
SCHEMBL28181895 0.81 PIK3CA (0.51) KDM4EACACAMAPTESR1ESR2
SCHEMBL19986175 0.79 CYP1A2 (0.55) KDM4EACACAEGFRUSP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9676767-B2 Indoloacridine-containing derivative, preparation process and use thereof, and organic luminescent device BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-06-13 US disclosed
US-9676767-B2 Indoloacridine-containing derivative, preparation process and use thereof, and organic luminescent device BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-06-13 US disclosed
US-9676767-B2 Indoloacridine-containing derivative, preparation process and use thereof, and organic luminescent device BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-06-13 US disclosed
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2016-02-18 US disclosed
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2016-02-18 US disclosed
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2016-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE AHR, CDYL, SLC18A1 MAOA 39/4885MAOB 49/4885KDM4E 2737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.